The non-digestible polysaccharide Arabinoxylan may be an effective oral adjuvant to support vaccine efficacy, according to a new pilot study involving 231 elderly participants.
Shoreline Biosciences and BeiGene collaborate on genetically modified natural killer cell therapies Shoreline Biosciences and BeiGene have announced an exclusive worldwide strategic collaboration to develop and commercialize a portfolio of natural killer (NK) based cell therapeutics.
The partnership will focus on a portfolio of NK-based cell therapeutics, using San Diego, California-headquartered Shoreline’s iPSC-derived NK cell tech. Shoreline will receive an upfront cash payment of $45m from BeiGene with the potential for additional development, regulatory and commercial milestone payments.
Shoreline’s proprietary platform focuses on iPSC-derived natural killer (NK) cells and macrophages that are optimized with precise and rational genetic reprogramming. The Shoreline NK cell and macrophage-based cell therapies are designed to provide ‘an effective and efficient means for targeting and killing tumors as well as repairing tissue homeostasis’.
COVID-19 vaccination via Vaxxas’ novel high-density microarray patch showed 'significantly enhanced' T-cell and spike-specific antibody responses compared to needle delivery, according to a pre-print preclinical study published this week.
A Phase 3 study of BAT1806, a proposed biosimilar referencing Actemra/RoActemra (tocilizumab), has shown equivalent efficacy and a comparable safety profile in patients with moderate-to-severe rheumatoid arthritis.
Engine Biosciences, a Singapore- and Silicon Valley-based company with an artificial intelligence-enabled technology platform that is designed to discover new biology targets and disease-causing links amongst known targets, has generated US$43m in a Series A funding round.